Antisense Therapeutics Ltd
ASX:ANP

Watchlist Manager
Antisense Therapeutics Ltd Logo
Antisense Therapeutics Ltd
ASX:ANP
Watchlist
Price: 0.084 AUD 1.2% Market Closed
Market Cap: 75.7m AUD

Relative Value

There is not enough data to reliably calculate the relative value of ANP.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ANP Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
196.7
Median 5Y
433.3
Industry
2.5
Forward
28.5
vs History
vs Industry
Median 3Y
-6.7
Median 5Y
-10.6
Industry
21.2
Forward
-3.6
vs History
vs Industry
Median 3Y
-9.3
Median 5Y
-10.1
Industry
16.3
vs History
vs Industry
Median 3Y
-9.2
Median 5Y
-10
Industry
23.8
vs History
vs Industry
Median 3Y
5.4
Median 5Y
7.6
Industry
2.1
vs History
vs Industry
Median 3Y
168.4
Median 5Y
351.4
Industry
2.6
Forward
24.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.2
vs History
vs Industry
Median 3Y
-5.7
Median 5Y
-8.5
Industry
12.5
Forward
-3.9
vs History
vs Industry
Median 3Y
-5.7
Median 5Y
-8.5
Industry
15.9
Forward
-3.9
vs History
vs Industry
Median 3Y
-8
Median 5Y
-8.4
Industry
14.6
vs History
vs Industry
Median 3Y
-7.9
Median 5Y
-8.4
Industry
17.2
vs History
vs Industry
Median 3Y
-64.4
Median 5Y
56.9
Industry
1.8

Multiples Across Competitors

ANP Competitors Multiples
Antisense Therapeutics Ltd Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Antisense Therapeutics Ltd
ASX:ANP
75.7m AUD 196.7 -6.7 -5.7 -5.7
US
Eli Lilly and Co
NYSE:LLY
738.5B USD 15.1 66.5 35.7 39
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
374.2B USD 4.2 17.2 12.5 16.5
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.5 18.7 13 14.9
CH
Roche Holding AG
SIX:ROG
205.9B CHF 3.4 24.9 9.3 10.9
CH
Novartis AG
SIX:NOVN
191B CHF 4.5 18.8 11 14.8
UK
AstraZeneca PLC
LSE:AZN
161.6B GBP 4 28.4 130.8 197.3
US
Merck & Co Inc
NYSE:MRK
207.3B USD 3.2 11.9 8.8 10.7
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
143.9B USD 2.3 18.3 7.8 10.9
P/E Multiple
Earnings Growth PEG
AU
Antisense Therapeutics Ltd
ASX:ANP
Average P/E: 25.6
Negative Multiple: -6.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
66.5
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.2
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.7
18%
1
CH
Roche Holding AG
SIX:ROG
24.9
32%
0.8
CH
Novartis AG
SIX:NOVN
18.8
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
28.4
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.9
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.3
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Antisense Therapeutics Ltd
ASX:ANP
Average EV/EBITDA: 433.7
Negative Multiple: -5.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.7
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13
13%
1
CH
Roche Holding AG
SIX:ROG
9.3
5%
1.9
CH
Novartis AG
SIX:NOVN
11
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130.8
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.8
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.8
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Antisense Therapeutics Ltd
ASX:ANP
Average EV/EBIT: 1 867.3
Negative Multiple: -5.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.5
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.9
14%
1.1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
14.8
10%
1.5
UK
AstraZeneca PLC
LSE:AZN
197.3
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.7
11%
1
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.9
10%
1.1